26 Dec

JNJ’s Stelara Witnessed High Growth in 3Q17

WRITTEN BY Daniel Collins FEATURED IN Company News, Insights, & Analysis

Stelara revenue trends

In 3Q17, Johnson & Johnson’s (JNJ) Stelara generated revenues of $1.1 billion, which reflected ~38% growth on a YoY basis and 14% growth on a quarter-over-quarter basis. In 3Q17, in the US market and international markets, Stelara generated revenues of $800 million and $324 million, respectively, compared to $561 million and $253 million in 3Q16.

Stelara reported YTD (year-to-date) September 2017 revenues of $2.9 billion compared to $2.3 billion in YTD September 2016. Stelara (ustekinumab) is used to treat moderate-to-severe Crohn’s disease, plaque psoriasis, and active psoriatic arthritis.

JNJ’s Stelara Witnessed High Growth in 3Q17

Recent approval

In October 2017, the U.S. Food and Drug Administration (FDA) approved Stelara for the treatment of individuals aged above 12 years (adolescents) with moderate to severe plaque psoriasis who are subjects for systemic therapy or phototherapy.

The U.S. FDA approval of Stelara is based on the results of the phase three trial that evaluated the safety and efficacy of the subcutaneous administration of Stelara in individuals aged 12 years or above with moderate-to-severe psoriatic arthritis. In the phase three trial, two-thirds of patients on Stelara responded to the week 12 primary endpoint after two doses at week 0 and 4. The safety parameters were consistent with earlier studies that were conducted on adults with plaque psoriasis.

Stelara’s peers in the plaque psoriasis marketplace include Celgene’s (CELG) Otezla, Valeant Pharmaceuticals’ (VRX) Siliq, and Eli Lilly’s (LLY) Taltz. In 3Q17, Otezla, Siliq, and Taltz reported revenues of $308 million and $151 million, respectively.

In 3Q17, Johnson & Johnson generated revenues of $3.2 billion from its immunology portfolio, which reflected ~6% growth on a YoY basis and 10% growth quarter-over-quarter.

The growth in sales of Johnson & Johnson’s immunology portfolio could boost the share prices of the Vanguard Dividend Appreciation ETF (VIG). Johnson & Johnson makes up about ~4.1% of VIG’s total portfolio holdings.

Latest articles

T-Mobile wants to showcase its strength before its first-quarter earnings release. T-Mobile is scheduled to report its first-quarter results on April 25.

Mondelēz (MDLZ) is scheduled to announce its first-quarter earnings results on April 30.

Freeport-McMoRan (FCX) is scheduled to release its first-quarter earnings on April 25.

23 Apr

How Ford Stock Is Faring ahead of Q1 Earnings

WRITTEN BY John Parker

Ford has risen 8.2% in April so far as compared to 2.6% gains in the S&P 500 Index.

23 Apr

Natural Gas Recovery Might Fade Away

WRITTEN BY Robert Scott

On April 22, natural gas prices settled at $2.52 per MMBtu—1.4% above the lowest closing level for active natural gas futures since June 8, 2016.

Kimberly-Clark (KMB) stock rose 5.4% on April 22 after the company released stronger-than-expected first-quarter results.